Distinguished in Peritonitis

Xueqing R. Yu

No. 19 Renmin Road, 
Zhengzhou, CN 
Distinguished in Peritonitis
No. 19 Renmin Road, 
Zhengzhou, CN 
OverviewLocationsClinical Research

Overview

Xueqing Yu practices in Zhengzhou, China. Yu is rated as a Distinguished expert by MediFind in the treatment of Peritonitis. Their top areas of expertise are IgA Nephropathy, Chronic Kidney Disease, Glomerulonephritis, Secondary Peritonitis, and Kidney Transplant.

Their clinical research consists of co-authoring 296 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 16 articles in the study of Peritonitis.

Locations

No. 19 Renmin Road, Zhengzhou, China
Other Locations
2 Anzhen Road, Beijing, 100029, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy
A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drug: Mezagitamab
Study Phase: Phase 1
Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study Low Dose Study
Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study Low Dose Study
Enrollment Status: Completed
Publish Date: September 23, 2021
Intervention Type: Drug
Study Phase: Not Applicable
View 1 Less Clinical Trial

296 Total Publications

Redox-active phenanthrenequinone as a molecular electron bridge for ultrastable Pd-catalyzed formic acid electrooxidation.
Redox-active phenanthrenequinone as a molecular electron bridge for ultrastable Pd-catalyzed formic acid electrooxidation.
Journal: Dalton transactions (Cambridge, England : 2003)
Published: November 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Yu's expertise for a condition
ConditionClose
    View All 32 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile